EHA 2026 | Clonal hematopoiesis & donor-derived leukemia: insights from an EHA-EBMT joint session
Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, briefly discusses the development of neoplasms in donor cells post-transplantation, noting that the recipient microenvironment can play a role in the development of leukemia. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I wouldn’t say transmitting the malignancies, you know, from donor to recipients, but we have neoplasms developed on the donor cells, you know, so the donor can be off of all these diseases, but the recipient can develop this. It’s a little bit complicated. Maybe we have this predisposition, genetic disposition in the donor cells, but the recipient microenvironment can, you know, play a role in the development of this leukemia, you know, for instance...
I wouldn’t say transmitting the malignancies, you know, from donor to recipients, but we have neoplasms developed on the donor cells, you know, so the donor can be off of all these diseases, but the recipient can develop this. It’s a little bit complicated. Maybe we have this predisposition, genetic disposition in the donor cells, but the recipient microenvironment can, you know, play a role in the development of this leukemia, you know, for instance. Yes, of course. I think now with all this new testing, you know, we are doing, etc., we can diagnose more and more donor-derived malignancies post-transplantation. It’s not a transmission of the disease, but a transmission of cells harboring these mutations and then the donor cells can develop this leukemia.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
